|Clinical use:||Diagnosis and subsequent monitoring of a diverse group of neoplasms that arise from the endocrine and nervous systems. The large number of potential serum tumour markers associated with tumours of this type necessitates a panel of markers being assembled resulting in the screens listed below. Patient symptoms may aid the clinician in selecting the appropriate screen.|
|Background:||Endocrine Diarrhoea Screen (EDS) – Measures those peptides that may be the cause of endocrine diarrhoea and includes Vasoactive Intestinal Peptide which increases secretions from the intestines, Neurokinin A which contracts smooth muscle and Pancreatic Polypeptide which affects gastro-intestinal secretions and increases gut motility.
Tests will be done in two groups:Group 1 – Chromogranin A, Neurokinin A, Gastrin and Pancreatic Polypeptide
Group 2 – Pancreastatin and Vasoactive Intestinal Peptide.
|Reference ranges:||Please see report|
|Patient preparation:||For suspected gastrinomas, patient off proton pump inhibitors for 2 to 3 days, then request Gastrin, Chromogranin A and Pancreatic Polypeptide.|
|Specimen requirements:||2 x EDTA Tubes (full)|
|Turnaround time:||4 weeks|
|Time limit for retrospective requesting:||N/A|
|Referred test:||Referred test|